Evaluation of the Trial to Assess Chelation Therapy (TACT): The scientific process, peer review, and editorial scrutiny

JAMA

Volumn 309, Issue 12, 2013, Pages 1291-1292

  Bauchner, Howard ^a   Fontanarosa, Phil B ^a   Golub, Robert M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; CHELATING AGENT; EDETIC ACID;

ANGINA PECTORIS; AUTISM; CEREBROVASCULAR ACCIDENT; CHELATION THERAPY; CLINICAL DECISION MAKING; CORONARY ARTERY DISEASE; EDITORIAL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MEASLES; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; RISK FACTOR; RUBELLA; FEMALE; MALE; NOTE;

ANGINA PECTORIS; CHELATING AGENTS; EDETIC ACID; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; STROKE;

EID: 84875554252     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.2761     Document Type: Editorial

References (5)

1. Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular outcomes in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013;309(12):1241-1250.
2. Office for Human Research Protections, Department of Health and Human Services. Correspondence regarding the Trial to Assess Chelation Therapy. http://www.hhs.gov/ohrp/detrm-letrs/YR09/may09b.pdf and http://www.hhs.gov/ohrp/ detrm-letrs/YR09/oct09a.pdf. Accessed March 8, 2013.
3. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children [retracted in: Lancet. 2004;363(9411):750]. Lancet. 1998;351(9103):637-641. (Pubitemid 28098447)
4. Callaway E. Chelation-therapy heart trial draws fire. Nature. 2012;491(7424):313-315.
5. Nissen SE. Concerns about reliability in the Trial to Assess Chelation Therapy (TACT). JAMA. 2013;309(12):1293-1294.